Physician profile

Natalia Alejandro

Obstetrics & Gynecology · Orlando, FL

NPI 1104019496

$669.25

in general payments reported to CMS, 2019-2025

16 companies · none reported in 2025

Payments by year

General and research payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Caldera Medical, INC $254.41 2020-2021
Pfizer INC. $73.26 2019-2022
Allergan, INC. $71.05 2019-2020
Exeltis, USA INC. $64.56 2021-2022
Abbvie INC. $46.58 2021-2022
Therapeuticsmd, INC. $28.54 2019-2020
Avion Pharmaceuticals $27.53 2019-2021
Medtronic, INC. $19.51 2022
Ethicon US, LLC $17.95 2022
Kci USA, INC. $14.76 2019
Organon LLC $14.37 2022
Duchesnay USA Incorporated $13.28 2019
Meditrina $12.43 2020
Minerva Surgical, INC $11.02 2019

2 companies reported research payments only; those appear in the research section below.

Research and ownership

$149.16 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Natalia Alejandro

$669.25

in general payments reported 2019-2025

Years
2019-2024
Top company
Caldera Medical, INC

https://glasscript.com/doctor/95249/natalia-alejandro

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.